|
Carcinoma, Basal Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that GLI1 has the potential to be a diagnostically useful marker for differentiating BCC from other skin malignancies and an interaction between the HH and Wnt signaling pathways may be involved in the development of BCCs.
|
31756206 |
2019 |
|
Carcinoma, Basal Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLI1 intranuclear trafficking by LAP2 isoforms represents a powerful signal amplifier in BCCs with implications for zinc finger-based signal transduction and therapeutics.
|
30503211 |
2019 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that Dsg2 enhances canonical hedgehog signaling downstream of Ptc1 to promote BCC development through the activation of phosphorylated Stat3 and regulation of Gli1 expression.
|
30291846 |
2019 |
|
Carcinoma, Basal Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate how PTCH1 loss results in aberrant regulation of SMO-independent mechanisms important for BCC biology and highlights a novel nuclear mechanism of SMO-GLI1 signaling that is unresponsive to SMO inhibitors.<b>Significance:</b> This study describes novel noncanonical Hedgehog signaling, where SMO enters the nucleus to activate GLI1, a mode that is unaffected by SMO inhibitors, thus prompting re-evaluation of current BCC treatment as well as new potential therapies targeting nuclear SMO.<i></i>.
|
29463581 |
2018 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Comparing the BCC group with the HC group, there was significantly higher expression of Shh, Ptch1, Ptch2, Smo and Gli1 proteins.
|
29424103 |
2018 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Studies involving mouse models have provided evidence that activation of the glioma-associated oncogene (GLI) family of transcription factors is a key step in the initiation of the tumorigenic program leading to BCC.
|
29987229 |
2018 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Perturbation of Hh signaling and activation of GLI1 (glioma-associated oncogene 1), a dedicated transcription factor for Hh pathway, are highly associated with several cancers, such as medulloblastoma and basal cell carcinoma.
|
29662197 |
2018 |
|
Carcinoma, Basal Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic inactivation of Il6 signaling in a mouse model of BCC significantly reduced in vivo tumor growth by interfering with HH/GLI-driven BCC proliferation.
|
29987839 |
2018 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sry-related high mobility group box 9 (SOX9) is a Hedgehog/glioma-associated oncogene homolog-regulated transcription factor known to be overexpressed in basal cell carcinomas (BCCs).
|
29550418 |
2018 |
|
Carcinoma, Basal Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination targeting of HDAC1 and aPKC robustly inhibited GLI1, lowering drug doses needed in vitro, in vivo, and ex vivo in patient-derived BCC explants.
|
29093271 |
2017 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Suppression of SHH decreased invasiveness through inhibition of matrix metalloproteinase (MMP)-2 expression, GLI1 expression, anchorage-independent proliferation, tumorigenicity, and tumor volume in vivo in CD24 siRNA transfected BCCs.
|
26797459 |
2016 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The stabilization of glioma-associated oncogene 1 (GLI1) mRNA by coding region determinant binding protein (CRD-BP) through the Wnt/β-catenin signaling pathway is implicated in the proliferation of colorectal cancer and basal cell carcinoma.
|
27036131 |
2016 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The primary outcome was the change in messenger RNA levels of the GLI family zinc finger 1 (GLI1) gene (HH-pathway target gene) in biopsy specimens of normal skin or BCC before and after treatment.
|
26765315 |
2016 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vitro findings were supported using human clinical samples, where we showed an inverse correlation between αvβ6 and Gli1 expression in different BCC subtypes and pancreatic cancers.
|
24573955 |
2014 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prkci is a HH target gene that forms a positive feedback loop with GLI and exists at increased levels in BCCs.
|
23446420 |
2013 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we show that IMQ can also directly repress HH signalling by negatively modulating GLI activity in BCC and medulloblastoma cells.
|
23995793 |
2013 |
|
Carcinoma, Basal Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that GLI1-mediated suppression of CYLD has a significant role in basal cell carcinoma progression.
|
21577203 |
2011 |
|
Carcinoma, Basal Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
In situ hybridization for GLI1 and PTCH1 was positive in basal cell carcinoma tumor cells, but was negligible in uninvolved or lesional psoriatic skin.
|
18754037 |
2009 |
|
Carcinoma, Basal Cell
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that different GLI1 genotypes alone or in combination with past sun exposure patterns as assessed in this study do not affect basal cell carcinoma risk.
|
19948058 |
2009 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GLI2 (GLI-Kruppel family member 2), a zinc finger transcription factor that mediates Hedgehog signaling, is implicated in the progression of an ever-growing number of human malignancies, including prostate and pancreatic cancer, as well as basal cell carcinoma of the skin.
|
19797115 |
2009 |
|
Carcinoma, Basal Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results identify the synergistic integration of GLI activator function and EGFR signaling as a critical step in oncogenic transformation and provide a molecular basis for therapeutic opportunities relying on combined inhibition of the HH/GLI and EGFR/MEK/ERK/JUN pathway in BCC.
|
19190345 |
2009 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Primary human keratinocytes retrovirally expressing GLI1(-) and GLI2(-) showed elevated levels of beta-tubulin III and ARC but not Neurofilament or GAP-43, suggesting that beta-tubulin III and Arc may be early targets of aberrant Gli expression in BCC, whereas expression of Neurofilament and GAP-43 are either later, downstream targets or under control of alternative pathways.
|
19479712 |
2009 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because the activation of hedgehog signals and the up-regulation of its critical transcriptional factor Gli1 are well documented in BCC, a molecular technique measuring Gli1 transcripts may aide the diagnosis.
|
15606671 |
2005 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Constitutive activation of hedgehog signaling, often caused by PTCH1 inactivation and leading to inappropriate activation of GLI target genes, is crucial for the development of several human tumors including basal cell carcinoma of the skin and medulloblastoma.
|
15521068 |
2005 |
|
Carcinoma, Basal Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Deregulation of the Shh pathway is associated with basal cell carcinoma (BCC) due to upregulation of GLI1 and GLI2.
|
15175043 |
2004 |